recent
year
number
benefici
health
effect
ascrib
reninangiotensin
system
ra
extend
beyond
lower
blood
pressur
primarili
mediat
via
angiotensinconvert
angiotensin
ang
ma
receptor
axi
moreov
thought
mere
system
effector
ra
compon
exist
within
tissu
highest
tissu
concentr
mrna
locat
gut
make
import
target
alter
ra
function
inde
genet
engin
recombin
probiot
promis
treatment
strategi
offer
deliveri
therapeut
protein
precis
ang
secret
lactobacillu
paracasei
lp
lpa
describ
regul
diabet
hypertens
howev
first
best
knowledg
propos
paradigm
relat
age
research
practic
manuscript
provid
proof
concept
use
technolog
wellcharacter
rodent
model
age
x
brown
norway
rat
primari
find
suggest
lpa
increas
circul
level
ang
acut
chronic
treatment
day
administ
week
futur
preclin
studi
explor
impact
treatment
gut
agesensit
distal
tissu
brain
muscl
recent
year
number
pleiotrop
effect
ascrib
reninangiotensin
system
ra
beyond
modul
blood
pressur
classic
canon
ra
thought
function
primarili
balanc
vasoconstrict
action
angiotensin
ii
angii
bind
receptor
action
bradykinina
potent
vasodilatori
substanc
howev
adjunct
ra
axi
recent
discov
function
bind
peptid
angiotensin
ang
ma
receptor
contrast
vasoconstrict
action
axi
angiotensinconvert
axi
induc
sever
benefici
physiolog
effect
figur
though
thought
mere
system
effector
compon
ra
includ
ang
exist
within
varieti
tissu
notabl
within
gastrointestin
tract
mrna
protein
present
signific
amount
small
intestin
brush
border
musculari
mucosa
propria
well
microvascular
endothelium
vascular
smooth
muscl
cell
addit
highest
tissu
concentr
mrna
found
termin
ileum
duodenum
colon
thu
make
gut
import
target
alter
ra
function
inde
genet
engin
recombin
probiot
purport
highli
promis
treatment
strategi
offer
potenti
efficaci
method
deliv
therapeut
protein
precis
high
degre
site
specif
sever
group
propos
rasrel
probiot
name
ang
secret
lactobacillu
paracasei
lp
lpa
regul
diabet
blood
pressur
hypertens
symptom
research
practic
manuscript
first
best
knowledg
propos
paradigm
relat
age
provid
proof
concept
wellcharacter
rodent
model
age
fisher
x
brown
norway
rat
also
provid
evid
establish
optim
dose
strategi
use
circul
ang
level
primari
outcom
ra
analyt
angii
ace
identifi
chang
arm
ra
acut
day
chronic
week
treatment
subject
male
rat
obtain
nation
institut
age
coloni
harlan
laboratori
indianapoli
femal
use
experi
coloni
nia
current
suppli
anim
expect
date
late
repeat
experi
femal
rat
strain
chosen
increas
longev
decreas
cumul
lesion
incid
compar
strain
anim
n
receiv
month
age
hous
individu
hour
light
hour
dark
cycl
specif
pathogenfre
facil
accredit
american
associ
accredit
laboratori
anim
care
univers
florida
anim
fed
standard
rodent
chow
kcal
fat
sucros
kcalg
diet
harlan
teklad
madison
wi
anim
allot
week
acclim
hous
condit
establish
baselin
rate
food
intak
bodi
weight
health
statu
bodi
weight
food
intak
monitor
daili
health
assess
includ
check
sudden
declin
bodi
weight
red
around
eye
nostril
ruffl
coat
open
tail
sore
haunch
postur
experiment
protocol
approv
univers
florida
anim
care
use
committe
accord
guid
care
use
laboratori
anim
design
rat
n
random
month
age
follow
treatment
group
week
ta
vehicl
lpa
deliv
concentr
lpa
chang
number
daysweek
lpa
deliv
rang
dose
chosen
base
preliminari
data
laboratori
indic
lpa
given
suffici
rais
ang
male
rat
although
chang
statist
signific
due
small
number
anim
data
shown
refin
dose
strategi
chose
smaller
larger
dose
day
rat
group
receiv
lpa
gavag
pb
control
stress
handl
handl
gavag
similar
degre
group
anim
weigh
food
intak
measur
daili
ensur
anorect
advers
effect
drug
administr
day
sublingu
blood
drawn
analys
analysi
circul
ra
compon
end
week
anim
euthan
rapid
decapit
tissu
dissect
futur
analys
construct
recombin
probiot
secret
ang
report
elsewher
manuscript
prepar
briefli
plasmid
addgen
plasmid
use
backbon
construct
express
vector
ang
peptid
express
secret
fusion
protein
chorea
toxin
bind
protein
subunit
b
ctb
separ
furin
cleavag
site
fusion
ctb
facilit
transmucos
transport
circul
tissu
uptak
receptormedi
endocytosi
result
plasmid
electropor
lp
electropor
describ
welker
et
al
wild
wildtyp
lp
lpa
cultur
mr
deman
rogosa
sharp
broth
bd
difco
houston
tx
supplement
erythromycin
hour
bacteria
harvest
centrifug
g
minut
resuspend
steril
pb
oral
gavag
extend
storag
harvest
bacteria
wash
pb
suspend
ta
buffer
trehalosetrehalos
sodium
sodium
ascorb
ascorb
skim
milk
frozen
small
aliquot
coloni
count
conduct
anim
experi
ensur
number
surviv
bacteria
anim
oral
gavag
cfu
kg
bodi
weight
equal
volum
buffer
gavagefeed
needl
inch
length
mm
ball
diamet
insert
esophagu
ensur
resist
advanc
fluid
inject
slowli
complet
needl
pull
straight
rat
toler
procedur
avers
outcom
observ
studi
supplementari
video
tongu
anesthet
isofluoran
rat
grasp
tweezer
vein
punctur
gaug
needl
blood
allow
drip
serum
tube
cotton
swab
use
stop
bleed
rat
recov
within
minut
home
cage
warm
disk
place
underneath
cage
concentr
ang
evalu
provid
proof
principl
lpa
effect
elev
ang
circul
also
measur
chang
circul
levelsact
main
effector
canon
adjuv
ra
axe
name
angii
ace
serum
level
ang
ang
ii
measur
use
commerci
elisa
kit
accord
instruct
provid
manufactur
cloudclon
corp
kati
tx
ang
enzo
life
scienc
inc
farmingdal
ny
ang
ii
briefli
ang
assay
plate
coat
monoclon
antibodi
specif
ang
incub
overnight
next
day
plate
wash
block
follow
addit
standard
sampl
incub
biotinyl
antiang
hour
follow
wash
step
streptavidinhorseradish
horseradish
peroxidas
peroxidas
hrp
ad
well
anoth
wash
tmb
amethylbenzidin
substrat
ad
absorb
read
nm
use
plate
reader
spectramax
molecular
devicedevic
sunnyval
ca
angii
assay
sampl
standard
ad
precoat
assay
plate
incub
antiang
ii
antibodi
hour
room
temperatur
follow
wash
step
streptavidinhrp
ad
well
anoth
wash
tmb
substrat
ad
absorb
read
nm
use
plate
reader
spectramax
molecular
devic
unit
state
standard
sampl
test
duplic
ang
ang
ii
concentr
calcul
rel
standard
curv
gener
serial
dilut
standard
provid
kit
serum
ace
activ
determin
use
assay
base
fluoresc
substrat
abzpheargli
dnp
prooh
ace
bachem
torranc
ca
r
system
inc
minneapoli
mn
publish
previous
briefli
ace
activ
assay
perform
black
plate
fluoresc
substrat
final
volum
per
well
well
ul
serum
sampl
load
along
assay
buffer
mm
tri
nacl
zncl
ph
fluoresc
intens
measur
use
spectramax
fluoresc
micropl
reader
molecular
devic
everi
second
excit
nm
emiss
nm
hour
activ
assay
perform
black
plate
fluorogen
peptid
substrat
final
volum
per
well
well
ul
serum
sampl
load
along
assay
buffer
mm
tri
nacl
zncl
ph
fluoresc
intens
measur
use
spectramax
fluoresc
micropl
reader
molecular
devic
llc
sunnyval
ca
everi
second
excit
nm
emiss
nm
hour
sampl
run
duplic
result
express
rel
fluoresc
unit
rfu
differ
ra
depend
measur
analyz
use
univari
analysi
varianc
anova
preplan
contrast
compar
dose
condit
control
condit
bodi
weight
food
intak
data
nonnorm
distribut
thu
perform
nonparametr
test
differ
median
baselin
across
week
studi
day
analys
conduct
use
commerci
avail
softwar
ibm
spss
statist
armonk
ny
differ
consid
statist
signific
p
observ
differ
treatment
level
weekli
bodi
weight
cumul
food
intak
cours
studi
day
ps
figur
indic
advers
effect
gener
health
figur
summar
result
describ
rat
week
group
significantli
higher
level
ang
day
p
p
respect
p
lower
level
angii
higher
ratio
ang
angii
time
point
level
significantli
higher
acut
group
effect
persist
chronic
group
ace
level
higher
acut
group
differ
observ
chronic
treatment
ratio
either
time
point
data
present
mean
sem
denot
dose
condit
significantli
differ
condit
respect
time
point
angiotensinconvert
ang
angiotensin
lp
lactobacillu
paracasei
ra
reninangiotensin
system
p
control
rat
angii
level
significantli
lower
group
day
ps
group
lower
day
p
p
p
howev
ang
angii
ratio
higher
group
day
p
p
day
p
p
ace
ratio
measur
addit
measur
activ
two
arm
ra
rat
week
group
significantli
higher
level
ace
day
ps
rel
control
differ
observ
day
level
significantli
higher
group
day
p
p
p
higher
group
day
p
p
differ
ratio
either
time
point
primari
purpos
studi
provid
proof
concept
use
recombin
probiot
secret
ang
increas
circul
concentr
ang
wellcharacter
rodent
model
age
rat
secondari
purpos
observ
impact
circul
ra
factor
name
angii
ace
use
oral
administ
probiot
provid
sever
potenti
advantag
tradit
drug
deliveri
includ
eas
administr
cost
product
burden
regulatori
approv
howev
mani
preclin
studi
util
method
may
correspond
close
util
human
studi
design
method
studi
includ
anim
strain
intervent
strategi
statist
approach
base
util
clinic
facilit
translat
studi
find
futur
clinic
trial
inde
found
lpa
increas
circul
level
ang
decreas
level
angii
dose
optim
indic
reason
efficaci
regimen
futur
preclin
studi
moreov
effect
recapitul
compar
ang
angii
across
group
well
acut
versu
chronic
administr
impact
ace
activ
ratio
two
less
dramat
acut
chronic
higher
group
ace
higher
dose
group
howev
acut
ratio
two
chang
either
time
point
reason
secondari
effect
easili
explain
although
could
may
identifi
posit
feedback
loop
higher
circul
ang
modul
level
two
enzym
whether
effect
specif
gutdeliv
ang
result
specif
impact
circul
level
ang
remain
empir
question
current
conduct
studi
address
issu
system
administ
ang
use
similar
design
outcom
variabl
clinic
human
applic
technolog
studi
high
impact
treatment
age
agerel
human
diseas
inde
human
intestin
tract
ie
gut
inhabit
trillion
microorgan
includ
speci
known
bacteria
commonli
overlook
human
health
diseas
treatment
gut
microorgan
encod
time
gene
human
genom
impact
host
physiolog
metabol
advanc
age
associ
loss
divers
number
gut
microbiota
lead
leaki
gut
increas
system
inflamm
reach
distal
organ
brain
moreov
gut
dysbiosi
tightli
link
develop
cognit
impair
physic
frailti
alzheim
diseas
support
concept
recent
demonstr
serum
zonulin
key
physiolog
regul
intestin
permeabl
elev
among
healthi
older
adult
compar
young
adult
zonulin
concentr
also
posit
correl
indic
inflamm
neg
correl
strength
physic
activ
find
human
indic
leaki
gut
could
primari
sourc
agerel
inflamm
preclin
model
thu
gut
appear
key
target
intervent
prevent
delay
revers
age
agerel
diseas
axi
also
recent
receiv
attent
connect
gut
microbiom
particularli
regul
amino
acid
transport
immun
function
intestin
moreov
evid
indic
gut
involv
regul
ecolog
gut
microbiom
attenu
intestin
inflamm
suffer
respons
epitheli
damag
fact
deficientmic
demonstr
increas
suscept
intestin
inflamm
transplant
microbiota
mice
germfre
wildtyp
host
induc
coliti
modul
axi
appear
promis
intervent
gut
health
result
studi
focu
lpa
influenc
circul
level
ang
necessarili
address
treatment
impact
gut
ra
modul
impact
downstream
target
gut
distal
tissu
inflamm
muscl
brain
exampl
addit
studi
dissoci
impact
lp
versu
lpa
activ
ra
alon
current
conduct
studi
address
question
supplementari
data
avail
journal
gerontolog
seri
biolog
scienc
medic
scienc
onlin
work
support
nation
institut
healthnat
institut
age
csc
twb
none
report
